Recent

% | $
Quotes you view appear here for quick access.

GlaxoSmithKline plc Message Board

  • jonslong805 jonslong805 Jul 21, 2009 9:31 PM Flag

    Glaxo buyout

    Absurd to think Glaxo would buy HGSI now. If Glaxo were inclined to take stupid risks, wouldn't it make more sense for them to announce a buyout of HGSI before the recent drug trial news? You don't think Glaxo, which is partnering on the drug costs/marketing (AND profits) knew of the results until after the press release?

    Which brings up the next question: Why would any company take such a big risk by buying a debt-ridden company unless they were certain that the drug would pass FDA muster (after the next trial outcome). This is hardly a certainty in light of Phase 2 problems and the recent statistically significant yet woefully tepid results of the test.

    The hopeful drug will be a dud if it ever gets past FDA scrutiny. Meanwhile, the bills continue to mount at this debt-burdened enterprise.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Rexahn ( Amex:RNN ) May be Little Penny Weight Biotech to Buy out because of ED Drug Zoraxel and a Robust Pipeline of Potenial Future Blockbuster Drugs, here is one I like ... Zoraxel for ED , here is why

      Zoraxel Could Knock Viagra Off Top Spot

      The big news in the world of erectile dysfunction medication is that Rexahn Pharmaceuticals has announced the beginning of phase two clinical trials for an exciting new medication called Zoraxel. Zoraxel has been developed to be an oral pill to be taken by men just before sexual activity in the same way as Viagra, Cialis and Levitra are.

      Unlike the other three erectile dysfunction drugs (Viagra, Cialis and Levitra) on the market Zoraxel is not a PDE-5 inhibitor so that people who suffer from the side effects of using this type of medication will be potential patients for the Zoraxel impotence drug. Zoraxel works by acting on the part of the central nervous system which controls sexual function. In testing Zoraxel has been identified as significantly improving the three main functions of sexual intercourse. It was noted that men experienced heightened sexual arousal, stronger erections and improved sexual release.

      If this is the case and it can be conclusively proved that Zoraxel has a significant effect on these three aspects of sexual intercourse it will be a revolutionary medication. The erectile dysfunction drugs Viagra, Cialis and Levitra work by increasing sexual function in men by giving them better erections but they do not have an effect on sexual desire and sexual release as it is claimed that Zoraxel does.

    • There is really no reason for GSK to buy them .. They already have the rights to market the drug , makes no sense to buy the company unless there are other drugs in the pipeline that GSK wants.. The ceo would rather sign license deals than outright takeover

    • Do u know anything about SEC regulations?

      If they knew the outcome of the trials they would have been barred from making a bid, unless the directors wanted to serve jail time.

 
GSK
44.16+0.12(+0.27%)Jul 26 4:02 PMEDT